Dermatological Drugs - Poland

Poland

The Dermatological Drugs market in Poland is expected to witness a significant growth in revenue, reaching €59.06m in 2024.
This growth is projected to continue with an annual growth rate (CAGR 2024-2029) of 5.24%, resulting in a market volume of €76.25m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in this market, with a projected revenue of €10,710.00m in 2024.
The dermatological drugs market in Poland is seeing a surge in demand for innovative treatments and a shift towards natural and organic products.

Key regions: United Kingdom, Canada, Japan, Europe, China

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for dermatological drugs in Poland has been steadily increasing over the years.

Customer preferences: Polish customers have shown a preference for topical dermatological drugs over systemic ones. This is due to the fact that topical drugs are easier to use and have fewer side effects compared to systemic drugs. Additionally, customers are becoming more interested in natural and organic ingredients in their skincare products.

Trends in the market: The market for dermatological drugs in Poland is expected to continue growing due to the increasing prevalence of skin diseases such as acne, psoriasis, and eczema. There has also been a rise in demand for anti-aging products in the country. Another trend in the market is the increasing popularity of online sales channels for dermatological drugs.

Local special circumstances: The Polish government has been implementing various measures to improve the healthcare system in the country, including increasing funding for healthcare and improving access to medical services. This has led to an increase in the number of patients seeking treatment for skin diseases. Additionally, the country's aging population has contributed to the rise in demand for anti-aging products.

Underlying macroeconomic factors: Poland has a growing economy and a large population, which has led to an increase in disposable income and spending power. This has resulted in customers being more willing to spend money on skincare products and dermatological drugs. The country's membership in the European Union has also led to an increase in foreign investment in the healthcare sector, which has contributed to the growth of the dermatological drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.